NCT02354937View on ClinicalTrials.gov

Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 13, 2015

Primary Completion Date

November 1, 2016

Study Completion Date

November 1, 2016

Conditions
Infection, Human Immunodeficiency VirusHIV Infections
Interventions
DRUG

GSK1265744 30 mg

White to almost white coated oval tablets with unit dose strength of 30 mg for oral administrations.

Trial Locations (2)

55404

GSK Investigational Site, Minneapolis

80228

GSK Investigational Site, Lakewood

Sponsors

Lead Sponsor

ViiV Healthcare
All Listed Sponsors
lead

ViiV Healthcare

INDUSTRY